sildenafil-citrate and Pressure-Ulcer

Pressure ulcer (PrU)-related hospitalisation and mortality are critical issues in medical and surgical patients. Although animal studies have suggested the beneficial effects of sildenafil on wound healing, related clinical data are lacking. This is the first clinical study that has evaluated the effects of topical sildenafil on PrU healing in human subjects. Enrolled patients were randomly allocated to receive topical sildenafil (10%) ointment or placebo daily. Wound healing was assessed visually and photographically by the change in wound score according to two-digit Stirling scale. Decreases in grades of the PrUs were significantly higher in sildenafil group compared with placebo group (P < 0·001). In addition, surface areas of ulcers in sildenafil group were significantly reduced compared to the control group at day 14 of intervention (P = 0·007). It appears that these effects may be mediated by improvement of microvascular reperfusion in the skin and soft tissue. Further study to emphasise the role of topical sildenafil in the prevention or treatment of PrUs in hospitalised patients is required.

Topics: Administration, Topical; Adult; Aged; Cohort Studies; Critical Care; Drug Administration Schedule; Female; Hospitalization; Humans; Iran; Male; Middle Aged; Piperazines; Pressure Ulcer; Purines; Sildenafil Citrate; Sulfonamides; Treatment Outcome; Vasodilator Agents; Wound Healing